DCF Tool

OMCL

Omnicell, Inc. – Electronic Computer Manufacturing
since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice
Analysis Results
Intrinsic Value $51.58
Latest Price $44.60
Relative Value 14% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 14.2%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 9.3%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 14.2%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 123 112
2024 140 117
2025 160 123
2026 183 128
2027 209 134
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 2920 million. This corresponds to a present value of 1720 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 615 million. Adding in the terminal value gives a total present value of 2330 million.

There are presently 45.2 million outstanding shares, so the intrinsic value per share is 51.58.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 881,812,000
Current Cash 330,362,000
Current Liabilities 428,446,000
Current Debt 0
Non-Cash Working Capital (NCWC) 123,004,000
Change in NCWC 79,359,000
EBIT -2,323,000
Tax Provision -8,101,000
Depreciation and Amortization 99,169,000
Capital Expenditure -60,740,000
Unlevered Free Cash Flow 115,465,000
Current Assets 780,702,000
Current Cash 349,051,000
Current Liabilities 876,158,000
Current Debt 488,152,000
Non-Cash Working Capital (NCWC) 43,645,000
Change in NCWC -23,418,000
EBIT 89,507,000
Tax Provision -11,842,000
Depreciation and Amortization 84,931,000
Capital Expenditure -58,335,000
Unlevered Free Cash Flow 92,685,000
Current Assets 829,414,000
Current Cash 485,928,000
Current Liabilities 276,423,000
Current Debt 0
Non-Cash Working Capital (NCWC) 67,063,000
Change in NCWC -51,969,000
EBIT 35,526,000
Tax Provision -2,845,000
Depreciation and Amortization 71,595,000
Capital Expenditure -54,866,000
Unlevered Free Cash Flow 286,000
Current Assets 483,238,000
Current Cash 127,210,000
Current Liabilities 236,996,000
Current Debt 0
Non-Cash Working Capital (NCWC) 119,032,000
Change in NCWC -6,330,000
EBIT 78,352,000
Tax Provision 12,595,000
Depreciation and Amortization 64,121,000
Capital Expenditure -61,664,000
Unlevered Free Cash Flow 61,131,192
Current Assets 397,134,000
Current Cash 67,192,000
Current Liabilities 204,580,000
Current Debt 0
Non-Cash Working Capital (NCWC) 125,362,000
Change in NCWC -12,007,000
EBIT 44,392,000
Tax Provision -2,113,000
Depreciation and Amortization 51,350,000
Capital Expenditure -54,374,000
Unlevered Free Cash Flow 29,361,000
Current Assets 367,121,000
Current Cash 32,424,000
Current Liabilities 212,536,000
Current Debt 15,208,000
Non-Cash Working Capital (NCWC) 137,369,000
Change in NCWC 48,951,000
EBIT 5,754,000
Tax Provision -21,484,000
Depreciation and Amortization 51,511,000
Capital Expenditure -30,541,000
Unlevered Free Cash Flow 75,675,000
Current Assets 315,408,000
Current Cash 54,488,000
Current Liabilities 180,912,000
Current Debt 8,410,000
Non-Cash Working Capital (NCWC) 88,418,000
Change in NCWC 31,137,000
EBIT 6,481,000
Tax Provision -2,551,000
Depreciation and Amortization 58,362,000
Capital Expenditure -29,165,000
Unlevered Free Cash Flow 66,815,000
Current Assets 264,128,000
Current Cash 82,217,000
Current Liabilities 124,630,000
Current Debt 0
Non-Cash Working Capital (NCWC) 57,281,000
Change in NCWC 12,115,000
EBIT 45,189,000
Tax Provision 15,484,000
Depreciation and Amortization 25,639,000
Capital Expenditure -12,547,000
Unlevered Free Cash Flow 55,265,248
Current Assets 283,384,000
Current Cash 125,888,000
Current Liabilities 112,330,000
Current Debt 0
Non-Cash Working Capital (NCWC) 45,166,000
Change in NCWC 8,323,000
EBIT 49,583,000
Tax Provision 17,986,000
Depreciation and Amortization 20,272,000
Capital Expenditure -22,602,000
Unlevered Free Cash Flow 37,189,890
Current Assets 233,778,000
Current Cash 104,531,000
Current Liabilities 92,404,000
Current Debt 0
Non-Cash Working Capital (NCWC) 36,843,000
Change in NCWC 1,477,000
EBIT 35,299,000
Tax Provision 11,050,000
Depreciation and Amortization 18,365,000
Capital Expenditure -20,452,000
Unlevered Free Cash Flow 23,553,827
Current Assets 180,756,000
Current Cash 62,313,000
Current Liabilities 83,077,000
Current Debt 0
Non-Cash Working Capital (NCWC) 35,366,000
Change in NCWC 12,274,000
EBIT 27,126,000
Tax Provision 10,897,000
Depreciation and Amortization 13,325,000
Capital Expenditure -15,574,000
Unlevered Free Cash Flow 26,233,473

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.